Suppr超能文献

肝脂肪变性、代谢功能障碍与死亡率风险:一项多国前瞻性队列研究的结果。

Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.

机构信息

Nutrition and Metabolism Branch, International Agency for Research On Cancer (IARC-WHO), 25 Avenue Tony Garnier, Lyon, 69007, France.

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

出版信息

BMC Med. 2024 Jun 3;22(1):221. doi: 10.1186/s12916-024-03366-3.

Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality.

METHODS

We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction-associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed.

RESULTS

Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3-17.1) years of follow-up. Compared to an FLI < 30, FLI ≥ 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27-1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09-1.60), CVD (HR = 2.06, 95% CI = 1.61-2.63) or other causes (HR = 1.21, 95%CI = 0.97-1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality.

CONCLUSIONS

Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.

摘要

背景

非酒精性脂肪性肝病 (NAFLD) 和代谢综合征 (MetS) 与非传染性疾病的病因有关。我们的研究旨在评估 NAFLD 和 MetS 与全因和特定原因死亡率之间的关联。

方法

我们使用 EPIC 队列的 15784 名随机亚组参与者的饮食、生活方式、人体测量和代谢生物标志物数据。使用脂肪肝指数 (FLI) 评估 NAFLD,使用修订后的定义评估 MetS。计算代谢功能障碍相关脂肪性肝病 (MAFLD) 的指数。使用多变量 Cox 比例风险模型评估这些指数与全因和特定原因死亡率的个体关联,以估计风险比 (HR) 和 95%置信区间 (95%CI)。作为子目标,还评估了新分类的代谢功能障碍相关脂肪性肝病 (MASLD) 和代谢和酒精相关肝病 (MetALD) 的适应风险关联。

结果

在 15784 名亚队列参与者中,在中位随访 15.6 年(IQR,12.3-17.1)期间共发生 1997 例死亡(835 例死于癌症,520 例死于心血管疾病,642 例死于其他原因)。与 FLI<30 相比,FLI≥60 与全因死亡率增加相关(HR=1.44,95%CI=1.27-1.63),与癌症(HR=1.32,95%CI=1.09-1.60)、心血管疾病(HR=2.06,95%CI=1.61-2.63)或其他原因(HR=1.21,95%CI=0.97-1.51)死亡风险增加。与无 MAFLD 个体相比,MAFLD 个体的死亡率风险也更高。患有 MetS 的个体有更高的全因死亡率风险,除了癌症特异性死亡率。MASLD 和 MetALD 与更高的全因死亡率风险相关。

结论

基于前瞻性队列的研究结果表明,有肝脂肪变性或代谢功能障碍的个体全因和特定原因死亡率风险更高。

相似文献

4
Impact of cardiometabolic risk factors for metabolic dysfunction-associated steatotic liver disease on mortality.
Nutr Metab Cardiovasc Dis. 2025 Jun;35(6):103965. doi: 10.1016/j.numecd.2025.103965. Epub 2025 Feb 26.
5
Steatotic liver disease-associated all-cause/cause-specific mortality in the United States.
Aliment Pharmacol Ther. 2024 Jul;60(1):33-42. doi: 10.1111/apt.18011. Epub 2024 Apr 22.
7
Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders.
BMC Gastroenterol. 2025 May 14;25(1):372. doi: 10.1186/s12876-025-03912-0.
10
Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.
Diabetes Metab J. 2025 Jan;49(1):80-91. doi: 10.4093/dmj.2024.0042. Epub 2024 Aug 28.

引用本文的文献

1
Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation.
Eur J Clin Invest. 2025 Aug;55(8):e70059. doi: 10.1111/eci.70059. Epub 2025 May 15.
3
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women.
Biomedicines. 2025 Apr 2;13(4):855. doi: 10.3390/biomedicines13040855.
4
Deciphering the roles of neddylation modification in hepatocellular carcinoma: Molecular mechanisms and targeted therapeutics.
Genes Dis. 2024 Dec 6;12(4):101483. doi: 10.1016/j.gendis.2024.101483. eCollection 2025 Jul.
7
Hu-lu-su-pian ameliorates hepatic steatosis by regulating CIDEA expression in AKT-driven MASLD mice.
Front Pharmacol. 2025 Jan 31;15:1503247. doi: 10.3389/fphar.2024.1503247. eCollection 2024.

本文引用的文献

1
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.
Nat Rev Gastroenterol Hepatol. 2024 Jan;21(1):46-56. doi: 10.1038/s41575-023-00846-4. Epub 2023 Oct 5.
2
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.
3
siMS score- method for quantification of metabolic syndrome, confirms co-founding factors of metabolic syndrome.
Front Genet. 2023 Jan 4;13:1041383. doi: 10.3389/fgene.2022.1041383. eCollection 2022.
5
Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study.
Metabolism. 2022 Aug;133:155222. doi: 10.1016/j.metabol.2022.155222. Epub 2022 May 28.
7
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
J Hepatol. 2022 Mar;76(3):506-517. doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 3.
8
9
Association of Metabolic Syndrome and Its Components With Risk of Stroke Recurrence and Mortality: A Meta-analysis.
Neurology. 2021 Aug 17;97(7):e695-e705. doi: 10.1212/WNL.0000000000012415. Epub 2021 Jul 28.
10
Mechanisms and disease consequences of nonalcoholic fatty liver disease.
Cell. 2021 May 13;184(10):2537-2564. doi: 10.1016/j.cell.2021.04.015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验